Human epithelial-type ovarian tumour marker beta-2-microglobulin is regulated by the TGF-β signaling pathway

Table 2 Association of B2M expression with the clinicopathological features of patients with EOC

Clinicopathological features	n	B2M expression		P value
Clinicopathological features	n	Positive (%)	Negative (%)	P value
Age at diagnosis
≤45	8	6 (75.00)	2 (25.00)	>0.999
>45	24	19 (79.17)	5 (20.83)	>0.999
Primary tumour size
≤2 cm	4	4 (100.00)	0 (0.00)	0.552
>2 cm	28	21 (75.00)	7 (25.00)	0.552
Multifocal tumours
Yes	15	13 (86.67)	2 (13.33)	0.402
No	17	12 (70.59)	5 (29.41)	0.402
LN metastasis
Yes	4	3 (75.00)	1 (25.00)	>0.999
No	28	22 (78.57)	6 (21.43)	>0.999
FIGO stage
I	17	12 (70.59)	5 (29.41)	0.207
II	7	5 (71.43)	2 (28.57)
III	8	8 (100.00)	0 (0.00)

The expression of B2M proteins was detected by immunohistochemistry. For comparison of B2M expression associated with age, primary tumour size, multifocal, LN metastasis, and clinical stages, Fisher’s exact test was applied
EOC epithelial ovarian cancer; n number of cases; Positive positive expression; Negative negative expression; LN lymph node

ISSN: 1479-5876